A detailed history of Morgan Stanley transactions in Viracta Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 134,544 shares of VIRX stock, worth $29,599. This represents 0.0% of its overall portfolio holdings.

Number of Shares
134,544
Previous 118,016 14.0%
Holding current value
$29,599
Previous $120,000 40.0%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$0.5 - $1.17 $8,264 - $19,337
16,528 Added 14.0%
134,544 $72,000
Q1 2024

Aug 16, 2024

BUY
$0.48 - $1.13 $14,724 - $34,662
30,675 Added 35.12%
118,016 $120,000
Q1 2024

May 15, 2024

BUY
$0.48 - $1.13 $14,724 - $34,662
30,675 Added 35.12%
118,016 $120,000
Q4 2023

Aug 16, 2024

SELL
$0.44 - $1.04 $20,769 - $49,091
-47,203 Reduced 35.08%
87,341 $49,000
Q4 2023

Feb 13, 2024

BUY
$0.44 - $1.04 $11,930 - $28,199
27,115 Added 45.02%
87,341 $49,000
Q3 2023

Nov 15, 2023

BUY
$1.03 - $1.58 $1,417 - $2,174
1,376 Added 2.34%
60,226 $62,000
Q2 2023

Aug 14, 2023

BUY
$0.89 - $2.13 $2,637 - $6,313
2,964 Added 5.3%
58,850 $82,000
Q1 2023

May 15, 2023

SELL
$1.38 - $2.29 $8,411 - $13,957
-6,095 Reduced 9.83%
55,886 $88,000
Q4 2022

Feb 14, 2023

SELL
$1.26 - $4.38 $5,305 - $18,444
-4,211 Reduced 6.36%
61,981 $90,000
Q3 2022

Nov 14, 2022

SELL
$3.32 - $5.69 $73,385 - $125,771
-22,104 Reduced 25.03%
66,192 $282,000
Q2 2022

Oct 27, 2022

BUY
$1.87 - $5.0 $38,510 - $102,970
20,594 Added 30.42%
88,296 $343,000
Q2 2022

Aug 15, 2022

BUY
$1.87 - $5.0 $38,510 - $102,970
20,594 Added 30.42%
88,296 $343,000
Q1 2022

Oct 27, 2022

SELL
$2.23 - $4.76 $45,924 - $98,027
-20,594 Reduced 23.32%
67,702 $322,000
Q1 2022

May 13, 2022

SELL
$2.23 - $4.76 $1.13 Million - $2.42 Million
-508,375 Reduced 88.25%
67,702 $322,000
Q4 2021

Feb 14, 2022

BUY
$3.37 - $7.91 $1.84 Million - $4.31 Million
544,576 Added 1728.76%
576,077 $2.1 Million
Q3 2021

Nov 15, 2021

BUY
$7.84 - $12.53 $246,967 - $394,707
31,501 New
31,501 $253,000

Others Institutions Holding VIRX

About Viracta Therapeutics, Inc.


  • Ticker VIRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,558,200
  • Market Cap $8.26M
  • Description
  • Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...
More about VIRX
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.